NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT06686394 2026-02-13
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT05319873 2025-05-13
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting